Project description:Enterolactone (EL) is a mammalian enterolignan produced in the intestine as a result of the microbial biotransformation of the dietary lignans. EL is a potential nutraceutical, with several health benefits, including anticancer and antimetastatic properties. Epidemiological data suggest a possible link between EL exposure and breast cancer risk. However, EL binds to estrogen receptor-α, produces estrogen-like effects on gene expression, and induces proliferation of MCF-7 breast cancer cells at a concentration of 10 µM. Here, we present RNA-seq data obtained from MCF-7 breast cancer cells treated with 10 µM EL for a period of 72 h, which captures the transcriptomic alterations associated with cell proliferation. The data are available from Gene Expression Omnibus (GEO, accession number GSE216876).
Project description:To inquire the a possible mechanism for heparin treatment improved cancer survival, three type of heparins: one standard heparin (unfractionated heparin (UFH), and two of low molecular weight heparin (LMWH) Fragmin and Clexane were used to treat cell for 24 hours. Total RNA was used for cDNA Microarray assay. Untreated cells were used as controls. Cell were treated by three type of heparins one standard heparin (unfractionated heparin (UFH), and two of low molecular weight heparin (LMWH) Fragmin and Clexane (40 IU/ml for each) were used to treat cell for 24 hours. Triplicate samples were prepared.
Project description:The MCF-7 were infected with either control adenovirus expressing B-galactosidase (Ad) or adenovirus expressing ERB (AdERbeta) for 72 h. For knockdown of the endogenous ERa in MCF-7 cells, cells were treated with siRNA for 24h (AdERbeta+SiERalpha). Then cells were treated with Veh (0.1% EtOH), 10 nM E2 or 1 uM BEs (botanical extracts) for 24h. Duplicate samples run; treatment after knockdown included a control treatment (V), estradiol (E2) or botanical extracts; genistein (Gen), S-equol, liquiritigenin (Liq)
Project description:Alcohol consumption is a risk factor for breast cancer. Little is known regarding the mechanism, although it is assumed that acetaldehyde or estrogen mediated pathways play a role. We previously showed that long-term exposure to 2.5 mM ethanol (blood alcohol ~0.012%) of MCF-12A, a human normal epithelial breast cell line, induced epithelial mesenchymal transition (EMT) and oncogenic transformation. In this study, we investigated in the human breast cancer cell line MCF-7, whether a similar exposure to ethanol at concentrations ranging up to peak blood levels in heavy drinkers would increase malignant progression. Short-term (1-week) incubation to ethanol at as low as 1-5 mM (corresponding to blood alcohol concentration of ~0.0048-0.024%) upregulated the stem cell related proteins Oct4 and Nanog, but they were reduced after exposure at 25 mM. Long-term (4-week) exposure to 25 mM ethanol upregulated the Oct4 and Nanog proteins, as well as the malignancy marker Ceacam6. DNA microarray analysis in cells exposed for 1 week showed upregulated expression of metallothionein genes, particularly MT1X. Long-term exposure upregulated expression of some malignancy related genes (STEAP4, SERPINA3, SAMD9, GDF15, KRT15, ITGB6, TP63, and PGR, as well as the CEACAM, interferon related, and HLA gene families). Some of these findings were validated by RT-PCR. A similar treatment also modulated numerous microRNAs (miRs) including one regulator of Oct4 as well as miRs involved in oncogenesis and/or malignancy, with only a few estrogen-induced miRs. Long-term 25 mM ethanol also induced a 5.6-fold upregulation of anchorage-independent growth, an indicator of malignant-like features. Exposure to acetaldehyde resulted in little or no effect comparable to that of ethanol. The previously shown alcohol induction of oncogenic transformation of normal breast cells is now complemented by the current results suggesting alcohol's potential involvement in malignant progression of breast cancer.
Project description:This is the microRNA experiment from the study of ethanol effects on the cultured cell line MCF-7, which is derived from a human malignancy. Cells were cultured in 6 well plates for a period of 4 weeks in the presence or absence of 25 mM ethanol. Cells were washed once with phosphate buffered saline pH 7.4, and RNA was extracted using the Mirvana kit for total RNA extraction. RNA samples were analyzed for microRNA prevalence by LC Sciences of Houston, Tx, USA. The results from 2 separate experiments were normalized and collected as the MultiArray Analysis Data presented here. The miR values are on an arbitrary scale.
Project description:Besides short-term non-genomic effects, the G-protein coupled estrogen receptor (GPER) also mediates long-term genomic effects of estrogen. The genomic effects of GPER activation are not completely understood. G1 is a selective GPER agonist, which is popularly used for addressing the effects of GPER activation. Here, we present transcriptomic (RNA-seq) data on MCF-7 cells treated with 100 nM, or 1 µM G1 for a period of 48 h. The data are available from GEO (accession number GSE188706).
Project description:This is the microRNA experiment from the study of ethanol effects on the cultured cell line MCF-7, which is derived from a human malignancy. Cells were cultured in 6 well plates for a period of 4 weeks in the presence or absence of 25 mM ethanol. Cells were washed once with phosphate buffered saline pH 7.4, and RNA was extracted using the Mirvana kit for total RNA extraction. RNA samples were analyzed for microRNA prevalence by LC Sciences of Houston, Tx, USA. The results from 2 separate experiments were normalized and collected as the MultiArray Analysis Data presented here. The miR values are on an arbitrary scale. There are 2 experiments, each containing a control (no ethanol) sample and a sample that was exposed to 25 mM ethanol for 4 weeks.
Project description:Independent studies have reported that circulating miRNAs have the potential as biomarkers; however, no consolidated guidelines for the discovery process are available. We developed a pipeline using innovative applications of existing bioinformatics methods to (1) face the inapplicability of the classical normalization methods, (2) detect global differences of miRNA distributions between the comparison classes and (3) develop a 'robust’ classifier. 78 samples (26 hemolyzed and 52 non hemolyzed) were 1:2 paired with caliper matching according to disease status, age at drawing and drawing year, starting from a total of 208 hybridized samples collected between 1987 and 2004 (including 94 paired samples according to tumor ER status, age at drawing, drawing year, time from surgery, 7 additional samples from 'no evidence of disease' (NED) patients, 10 references, 1 healthy donor and 2 replicated samples)